Flare Therapeutics is a biotechnology company seeking to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
03/22/2023 | Series B | $125MM | $xx.xx | $293.11MM | GordonMD Global Investments, Pfizer, Boxer Capital, Casdin Capital, Eventide Asset Management, Invus Financial Advisors, Nextech Invest, Third Rock Ventures, Agent Capital, Eli Lilly, Memorial Sloan Kettering Cancer Center, Novartis, Pavilion Capital, ShangBay Capital | |
Price per Share
$xx.xx
Shares Outstanding
103,880,993
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
GordonMD Global Investments, Pfizer, Boxer Capital, Casdin Capital, Eventide Asset Management, Invus Financial Advisors, Nextech Invest, Third Rock Ventures, Agent Capital, Eli Lilly, Memorial Sloan Kettering Cancer Center, Novartis, Pavilion Capital, ShangBay Capital
|
||||||
05/13/2021 | Series A | $82MM | $xx.xx | $136.67MM | Third Rock Ventures, Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, Eventide Asset Management | |
Price per Share
$xx.xx
Shares Outstanding
82,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Third Rock Ventures, Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, Eventide Asset Management
|